Medicus Pharma Acquires Clinical-Stage Drug Development Company Antev Limited

Paul, Weiss advised biotech company Medicus Pharma Ltd. on its acquisition of Antev Limited, a UK-based clinical-stage drug development company. Antev is currently developing Teverelix, a next-generation product for prostate cancer patients with high cardiovascular risk and people with urinary retention issues due to an enlarged prostate.

Under the transaction, Medicus has acquired 98.6 percent of Antev’s issued and outstanding shares for consideration of cash and Medicus common shares. Antev’s former shareholders will be entitled to receive additional contingent consideration tied to potential future U.S. Food and Drug Administration Phase 2 and New Drug Application approvals.

The Paul, Weiss team was led by corporate partners Benjamin Wilkinson, Will Aitken-Davies and Christopher Cummings, and included tax partners Matthew Jordan, Deeksha Rathi and Kyle O’Sullivan.